ATC Group: D11AX10 Finasteride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D11AX10 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D11 Other dermatological preparations
3 D11A Other dermatological preparations
4 D11AX Other dermatologicals
5 D11AX10 Finasteride

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 mg

Active ingredients in D11AX10

Active Ingredient Description
Finasteride

Finasteride is a competitive inhibitor of human 5α-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.